Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Autolus Therapeutics (AUTL) Revenue (2017 - 2025)

Historic Revenue for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to $21.2 million.

  • Autolus Therapeutics' Revenue changed N/A to $21.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $51.1 million, marking a year-over-year increase of 40621.78%. This contributed to the annual value of $10.1 million for FY2024, which is 49599.53% up from last year.
  • Autolus Therapeutics' Revenue amounted to $21.2 million in Q3 2025.
  • In the past 5 years, Autolus Therapeutics' Revenue registered a high of $21.2 million during Q3 2025, and its lowest value of $236.0 during Q3 2021.
  • In the last 5 years, Autolus Therapeutics' Revenue had a median value of $1.8 million in 2022 and averaged $5.8 million.
  • In the last 5 years, Autolus Therapeutics' Revenue tumbled by 9994.61% in 2021 and then surged by 100371355.93% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Revenue (Quarter) stood at $236.0 in 2021, then skyrocketed by 1550323.73% to $3.7 million in 2022, then plummeted by 88.9% to $406000.0 in 2023, then crashed by 92.86% to $29000.0 in 2024, then skyrocketed by 72982.76% to $21.2 million in 2025.
  • Its Revenue was $21.2 million in Q3 2025, compared to $20.9 million in Q2 2025 and $9.0 million in Q1 2025.